The three RUNX family members are lineage specific master regulators, which also have important, context-dependent roles in carcinogenesis as either tumor suppressors or oncogenes. Here we review evidence for such roles in breast cancer (BCa). RUNX1, the predominant RUNX family member in breast epithelial cells, has a tumor suppressor role reflected by many somatic mutations found in primary tumor biopsies. The classical tumor suppressor gene RUNX3 does not consist of such a mutation hot spot, but it too seems to inhibit BCa; it is often inactivated in human BCa tumors and its haploinsufficiency in mice leads to spontaneous BCa development. The tumor suppressor activities of RUNX1 and RUNX3 are mediated in part by antagonism of estrogen signaling, a feature recently attributed to RUNX2 as well. Paradoxically, however RUNX2, a master osteoblast regulator, has been implicated in various aspects of metastasis in general and bone metastasis in particular. Reciprocating the anti-estrogenic tumor suppressor activity of RUNX proteins, inhibition of RUNX2 by estrogens may help explain their context-dependent anti-metastatic roles. Such roles are reserved to non-osseous metastasis, because ERa is associated with increased, not decreased skeletal dissemination of BCa cells. Finally, based on diverse expression patterns in BCa subtypes, the successful use of future RUNX-based therapies will most likely require careful patient selection.
The mammalian RUNX family of transcription factors comprises three members, RUNX1, RUNX2 and RUNX3, which have pivotal roles in both normal development and neoplasia. 1 Despite their structural similarities, RUNX proteins have divergent physiological roles; RUNX1 is required for definitive hematopoiesis, 2 RUNX2 has fundamental roles in the differentiation of osteoblasts and chondrocytes, [3] [4] [5] and RUNX3 is involved in gastrointestinal and neuronal development. [6] [7] [8] Inherited mutations in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy, 9 and RUNX2 mutations cause the dominant autosomal skeletal disease cleidocranial dysplasia. 10 In cancer, RUNX act as either tumor suppressors or oncogenes depending on cellular context. 1, 11 RUNX1 is a frequent target of translocations and other mutations in hematopoietic malignancies, and RUNX3, located on chromosome 1p36, resides in a deletion hotspot found in diverse cancers of epithelial, hematopoietic and neuronal origins. 12 Tumor suppressor activity in breast cancer (BCa) has been attributed to all three RUNX proteins, [13] [14] [15] whereas RUNX2 is increasingly recognized as prometastatic in breast (and prostate) cancer progression. 11, [16] [17] [18] [19] [20] Here we review the dual functions of RUNX proteins in BCa and their relationships with estrogen signaling.
RUNX PROTEINS ARE TUMOR SUPPRESSORS
All three mammalian RUNX family members have been implicated in tumor suppression. The frequent functional inactivation of RUNX1 and RUNX3 observed in hematopoietic and solid tumors of diverse origins have been extensively reviewed, [21] [22] [23] [24] and Table 1 summarizes reported abnormalities implicating each of the RUNX proteins as a tumor suppressor in various cancer types.
RUNX1 AS A BCa SUPPRESSOR
In addition to their most notable roles in hematopoietic cells, bone cells and neurons, the three RUNX genes are also expressed in the normal mammary gland, and their mRNA levels fluctuate during cycles of pregnancy, lactation and involution. 25 RUNX1 is the predominant RUNX family member expressed in human breast epithelial cells 13, 26, 27 (Figure 1a ) and the protein is readily detected in both the basal and the luminal cell layers. 26 The most compelling evidence for its role in inhibiting BCa is the somatic mutations recently observed in RUNX1 (and not RUNX2 or RUNX3) in tumors from the Washington University BRC77 study 28 and in the cohort of BCa patients studied in The Cancer Genome Atlas pilot project 29 ( Figure 1b) . Furthermore, RUNX1 was one of 17 genes whose expression pattern predicted BCa metastasis; 30 its expression is less abundant in BCa compared to normal breast epithelial cells, and it progressively decreases with increasing BCa tumor aggression. 31 Finally, experimental Ras-mediated transformation of basal-like MCF10A cells was associated with loss of RUNX1; 31 and RUNX1 silencing in another study with MCF10A cells led to the formation of abnormal, hyperproliferative acinar structures in 3D cultures.
epithelial-to-mesenchymal transition (EMT) 32 and it may cooperate with FOXO signaling to protect ER-negative BCa cells from oxidative stress. 13 In ER-positive cells, however, we believe RUNX1 attenuates oncogenic effects of estrogens (Figure 2a ) mainly through physical interaction with ERa. 33 In fact, all but one RUNX1 somatic mutations found so far are in ERa-positive tumors. 28, 29 RUNX3 AS A BCa SUPPRESSOR Evidence suggesting a role for RUNX3 in inhibiting various malignancies is cited in Table 1 14,34-36 and the literature on the tumor suppressor role of RUNX3 specifically in BCa has been recently reviewed. 24 Most notably, RUNX3 hemizygous female mice develop spontaneous ductal carcinoma, 14 attributable to increased estradiol signaling owing to partial loss of ERa destabilization by RUNX3 14 ( Figure 2a) . Expression of RUNX3 decreases during human BCa progression and high RUNX3 levels are associated with favorable prognosis. 35 As in other malignancies, RUNX3 is frequently inactivated in BCa by promoter hypermethylation, genetic deletion, and protein mislocalization. 34, 35, [37] [38] [39] [40] [41] [42] RUNX3 promoter hypermethylation in response to estradiol has been observed in mammospherederived cells, which may contribute to the oncogenic activity of estradiol in breast epithelial cells.
43
RUNX2 AS A BCa SUPPRESSOR RUNX2 is expressed in the developing mammary gland during embryogenesis 5 and puberty, and its mRNA levels in glands of 5-week-old female mice are highest in the terminal end buds. 44 Suggesting a physiological role in mammary epithelial cells, RUNX2 regulates transcription of beta-casein, 45 a mammary gland-specific gene, and osteopontin, 46 which is expressed in these cells during pregnancy and lactation. A growth-suppressive role for RUNX2 was demonstrated in osteoblasts, [47] [48] [49] and its tumor suppressor role in hormone carcinogenesis has been suggested based on the antagonism of ERa-and androgen receptor-mediated transcription in breast and prostate cancer cells, respectively. 50, 51 In the MCF7/Rx2 dox BCa cell line, RUNX2 diminished E2-mediated colony formation in soft agar. 15 This was attributable to the RUNX2-mediated general attenuation of the transcriptional response to E2, demonstrated by genome-wide mRNA analysis. 15 Consistent with this in vitro finding, inhibition of estrogen signaling by letrozole treatment of BCa patients resulted in a global increase of RUNX2 activity. 15 Antagonism of estradiol signaling by RUNX2 in vitro was particularly interesting for a gene set, heretofore R2iEs, which was inhibited by RUNX2 (R2i) and stimulated by estradiol (Es). The short-term response of the R2iEs gene set to letrozole treatment predicted clinical outcome better than other estradiol-regulated gene sets. Thus, the R2iEs gene set, which is enriched for polo-like kinaserelated mitotic pathway genes, 15 represents a critical growth regulatory node where the mitogenic property of estrogens meets the anti-proliferative effect of RUNX2 in BCa cells. Finally, it is important to note that RUNX2 can have either a negative or a positive role in BCa initiation depending on cellular context; contrasting its aforementioned tumor suppressor role in the ERa-positive MCF7 BCa cell line, 15 RUNX2 overexpression increased proliferation and induced abnormal acini formation Figure 1 . RUNX1, highly expressed in breast epithelial cells, is frequently mutated in BCa. (a) RNA-sequencing data for RUNX1, RUNX2 and RUNX3 in human brain, heart, lymph node and breast tissues and in Human Mammary Epithelial Cells (HMEC) were produced by Wang et al. 27 and displayed using the UCSC Genome Browser (http://genome.ucsc.edu). (b) Lollipop plot of RUNX1 somatic mutations identified by The Cancer Genome Atlas project 29 and the Washington University BRC77 study. 28 These studies indentified only one synonymous mutation in RUNX2 and none in RUNX3. Blue box represents the Runt DNA-binding domain.
in the ERa-negative MCF10A cell line. 17 Also contrasting its tumor suppressor activity is the pro-metastatic property of RUNX2, which will be discussed in detail under the next subtitle.
Multiple mechanisms could contribute to the antagonism of ERa by RUNX2. First, RUNX2 decreases ERa mRNA and protein levels in BCa cells; 15 this inhibition could occur at the transcriptional level because it has been shown, albeit in prostate cancer cells, that RUNX2 is recruited to the ERa proximal promoter. 52 Second, because RUNX2 binds ERa's DNA-binding domain, 51 the interaction may result not only in decreased association of RUNX2 with its target genes, 15, 51 but also in decreased association of ERa with its targets. 15 Consistent with this idea, re-analysis of two recent data sets 33, 53 indicated that genomic ERa targets are more likely to be antagonized by RUNX2 compared with non-genomic targets. 15 Two observations suggest that this mechanism is likely specific for RUNX2. First, in contrast to the interaction of RUNX2 with the DNAbinding domain of ERa, 51 the reported interaction with RUNX3 involves the hinge region of ERa. 24 Second, the C-terminus of RUNX2, which contains its ERa-binding region, 51 is not conserved in other RUNX proteins.
1 Thus, whereas the BCa-suppressor activities of both RUNX2 and RUNX3 are at least in part attributable to inhibition of ERa, the respective molecular mechanisms are likely distinct.
ONCOGENIC PROPERTIES OF THE RUNX FAMILY AND THE EMERGING ROLE OF RUNX2 IN METASTASIS
Insertional mutagenesis studies in murine models have assigned oncogenic properties to each of the three RUNX genes. [54] [55] [56] [57] [58] [59] [60] [61] [62] Furthermore, RUNX1 63 synergized with c-Myc in murine lymphoma development, and acted as an oncogene in the mouse skin by promoting epithelial cell proliferation. 64 In humans, the 21q region that includes RUNX1 is amplified in a small, aggressive sub set of childhood B-cell lineage acute lymphoblastic leukemia. [65] [66] [67] [68] Moreover, RUNX1 was among the most highly up-regulated genes in invasive endometrial carcinoma. [69] [70] [71] In BCa RUNX1-mediated tethering of ERa to target genes 33 may also contribute to breast hormone carcinogenesis. There is also some evidence that RUNX3, a classical tumor suppressor, can act to promote human cancers. Possibly related to promoter demethylation, the gene is over-expressed in carcinomas of the head and neck, 72 skin 73 and ovary. 74 Whereas most of the cancer-related literature on RUNX genes, in particular RUNX1 and RUNX3, concerns their tumor suppressor activities, RUNX2 is increasingly recognized in the cancer field for its oncogenic properties. RUNX2 was the most frequent target for viral insertions in murine retroviral mutagenesis screens, 61, 68 and similar to RUNX1, it cooperated with c-Myc, 75 as well as with CBFb-SMMHC, 76 to induce murine hematologic cancers. Amplification of RUNX2 on human chromosome 6p21 was related to osteosarcoma, 77,78 a malignancy arising from osteoblasts, the cells in which RUNX2 has its most notable developmental role. Furthermore, RUNX2 is overexpressed in carcinomas of the colon, 79 pancreas 80 and thyroid. 81 In animal models of various malignancies including the prostate, 82 lung 83 and thyroid cancer, 84 an increase in RUNX2 observed early during cancer development likely induces EMT and local invasion. However, as discussed in detail below, most of the published work implicating RUNX2 in promoting cancer relates to prostate cancer and BCa. 11, [16] [17] [18] [19] [20] [85] [86] [87] The expression of bone-phenotypic genes in metastatic tumors was initially pursued in the context of prostate cancer, with the idea that the frequent dissemination of prostate cancer cells to bone may rely on osteomimetic mechanisms. 88 A similar line of work followed in the context of BCa, which also metastasizes to bone with high frequency. 89 Early studies documented ectopic expression in prostate cancer and BCa cells of CXCR4, MMPs, OPN, BSP, RANKL 20, [90] [91] [92] [93] [94] [95] [96] and finally RUNX2, the osteoblast master regulator. 97, 98 RUNX2 was shown to prevent prostate cancer cell apoptosis by stimulating the expression of survivin and Bcl2. 82, 99 Increased levels of RUNX2 during prostate and breast tumor growth was linked to BMP7-mediated protection of cancer cells against apoptosis. [100] [101] [102] Perturbations of RUNX2 in prostate cancer and BCa cells abolished their ability to form osteolytic lesions in mouse xenograft model. 16, 20, 103 Recent studies have implicated RUNX2 in metastasis beyond a role in bone homing, including local invasiveness as well as growth of tumors that have already metastasized to the skeleton. Induction of RUNX2 in prostate cancer cells in vitro stimulated expression of numerous genes with known roles in EMT, invasiveness, extracellular matrix degradation, angiogenesis and osteolysis, 11, 15, 17, 19, 20, 86, 104, 105 with some of these metastatic phenotypes possibly depending on RUNX2-stimulated protein secretion. 52 Thus, whereas RUNX2 initiates an osteoblastic program in mesenchymal pluripotent cells, 106 its ectopic expression in cancer cells initiates a transcriptional program responsible for various aspects of metastasis, including but not limited to bone homing.
Interestingly, manipulation of RUNX2 in prostate cancer and BCa cells modulated the expression of several genes implicated in osteoclast differentiation and bone resorption, including OPG, CSF2, SPHK1, PTHrP, IL8 and several MMPs. 15, [17] [18] [19] [20] 104, 107 Stimulation of bone resorption by prostate cancer cells is not unlike the increased resorption leading to the osteolytic lesions typically associated with BCa bone metastasis, even though the co-stimulation of bone formation predominates in most cases of prostate cancer bone metastases, resulting in osteoblastic tumors. 108 It is the high bone turnover induced by both prostate cancer and BCa cells that elicits a vicious cycle whereby matrixembedded growth factors, normally reserved to secure sufficient bone formation, are now released at higher rates and hijacked to promote tumor cell growth. 108, 109 RUNX2-mediated tumor cell-driven osteoclastogenesis represents mimicry of the osteoclastogenic role that RUNX2 has in the osteoblast lineage. [110] [111] [112] [113] [114] [115] Confirming the significance of RUNX2 in human BCa aggression, Onodera et al. 87 showed that RUNX2 immunohistochemical labeling index in primary tumor biopsies positively correlated with disease progression and metastasis. The prometastatic properties of RUNX2 in the MCF7/Rx2 dox BCa cell line critically depended on its target gene SNAI2, as knockdown of SNAI2 abolished RUNX2-driven EMT and invasiveness 86 ( Figure 3 ). Conceivably, RUNX2-driven EMT in BCa cells 86 recapitulates a role that RUNX2 has during normal branching morphogenesis, as suggested by its co-expression with EMT-related genes in mammary gland terminal end buds. 
ROLE OF RUNX2 AND ESTROGEN SIGNALING IN BCa METASTASIS
Estrogen signaling, which promotes BCa initiation, has a paradoxical anti-metastatic role in advanced disease, [116] [117] [118] and this is attributable in part to inhibiting the expression of RUNX2 target genes, including SNAI2 51, 86, 119 (Figure 3) . Relationships among RUNX2, SNAI2 and ERa in vivo are demonstrable in gene expression profiles of BCa biopsies, where SNAI2 positively correlates with RUNX2 activity, and the RUNX2/SNAI2 axis negatively correlates with ERa. 86 Furthermore, in the study of Onodera et al., the negative correlation of RUNX2 with diseasefree survival was much stronger for ERa-negative compared with ERa-positive tumors. 87 Thus, antagonism between RUNX2 and estrogen signaling in BCa has a role in two distinct contexts. First, as discussed earlier, ERa signaling is targeted by RUNX2 (as well as RUNX1 and RUNX3), acting to suppress tumor initiation (Figure 2a) . Second, the beneficial effect of ERa signaling in late-stage disease is attributable in part to inhibition of RUNX2 activity, now acting to promote metastasis ( Figure 2b ).
As mentioned above, the osteomimetic property of prostate and later BCa was initially considered in the context of bonehoming. However, consistent with the role of RUNX2 in EMT and invasion, which promote early metastatic events, the predominant contribution of RUNX2 to the metastatic process is not necessarily bone-specific. 86 Other signaling pathways, such as Src, increase the predilection of a sub set of primary BCa cells to bone. 120 These cells then give rise to metastases with a gene expression signature that specifically reflects adaptation to bone, 121 as opposed to the gene signature of BCa lung metastases, which better reflects general metastatic properties. 122 Because BCa metastases to bone versus other organs are processes with distinct molecular characteristics, it is not surprising that they exhibit differential sensitivity to estrogen signaling. Whereas ERa is negatively correlated with nonosseous metastasis, 86 attributable in part to antagonism of the RUNX2/SNAI2 axis, it is positively correlated with bone metastasis 86, 120, 123 ( Figure 3) . Thus, ERa in bone-seeking tumors not only permits expression of RUNX2 target genes, but in fact appears to promote bone metastasis. The co-existence of RUNX2 and ERa in bone-seeking BCa cells may even result in positive interaction at regulatory elements of genes that promote bonehoming and growth within this microenvironment. Indeed, although RUNX2 and estrogen signaling are generally antagonistic, expression profiling of MCF7/Rx2 dox cells also disclosed genes that are additively or synergistically regulated by the two pathways. 86 It will be interesting to test the role of these genes in bone metastasis and to compare the in vivo effects of RUNX2 on growth of ERa-positive versus ERa-negative BCa cells in bone versus non-osseous tissues.
RUNX PROTEINS IN BCa SUBTYPES
BCa is a heterogeneous disease in terms of cell of origin, clinical progression and drug responsiveness. Based on their intrinsic gene expression profiles, BCa tumors can be classified into distinct molecular subtypes: luminal-like A, luminal-like B, basal-like, HER2-positive and normal breast-like. 124, 125 Figure 4 describes the expression/activity of the three RUNX proteins, along with ERa and HER2, in a cohort of 557 tumors compiled previously 86 and stratified per subtype based on the PAM-50 algorithm. 126 Most obviously, high RUNX2 activity and high RUNX3 expression characterize the ERa-negative basal-like tumors, attributing to the reported negative correlation between these two RUNX members and ERa in BCa cells. 14, 15, 24, 43, 51 High RUNX2 activity was also present in some HER2 enriched tumors, but not in the luminal subtypes, consistent with the positive correlation previously observed between RUNX2 and HER2. 87 Finally, Figure 4 demonstrates a negative correlation between RUNX1 and RUNX2/3 and a strong positive correlation between RUNX2 activity and RUNX3. The interdependent expression of RUNX members in BCa (Figure 4) Figure 3 . Roles of RUNX2 and ERa in BCa metastasis. According to this working model, the RUNX2/SNAI2 axis promotes early metastatic events (e.g., EMT, invasion, intravasation) and bone metastasis. ERa antagonizes RUNX2 during the early metastatic events but operates along with the RUNX2/SNAI2 axis during bone metastasis. Figure 4 . RUNX genes in BCa subtypes. Each tumor from a heterogeneous cohort of 557 BCa patients 86 was subtyped according to the PAM-50 algorithm 126 (courtesy of Dr Charles Perou). The values for RUNX1, RUNX3, HER2 and ESR1 represent the signal intensity associated with probe sets 210805_x_at, 26 204197_s_at, 216836_s_at and 205225_at, 120 respectively (Affymetrix, Santa Clara, CA, USA). Because of the ambiguity with the RUNX2 probe sets in the early Affymetrix arrays used to profile mRNA expression, the RUNX2 values are those of a metagene defined as the average normalized expression of the top 100 RUNX2-stimulated genes in MCF7/Rx2 dox BCa cells. 15 is in line with the inverse relationships observed between RUNX1 and RUNX3 mRNA in B cells 127, 128 and RUNX1 and RUNX2 mRNAs during skeletal development. 129 These relationships are attributable in part to the high similarities among the DNA-binding domains of the three RUNX proteins 1 and the consequential similarities among their DNA binding elements 52, 130, 131 and their transcriptomes. 132 Also likely having a role in the observed relationships between expression of different RUNX proteins are the RUNX-binding elements in the RUNX gene promoters 52, 133, 134 and their subsequent cross-regulation. 127, 128 CONCLUDING REMARKS RUNX proteins have unique and often opposing roles in BCa. The global reciprocal inhibitory effects between estrogen and RUNX2 signaling, and the clinical relevance of this antagonism 15, 86 provide novel insight into hormone-driven carcinogenesis. They may ultimately contribute to a better understanding of how RUNX genes switch their function from tumor suppressors to oncogenes. They may also shed light on the contribution of estrogen signaling to bone, but not other metastatic processes. So far, RUNX1 and RUNX3 were shown to exhibit only tumor suppressor activities in BCa, 13, 24 whereas RUNX2 was capable of acting either as a tumor suppressor or as an oncogene depending on cellular context. 15, 17, 86 Given the solid evidence for a tumor suppressor role for RUNX3 in BCa, its preferential expression in the basal-like, typically aggressive BCa subtype, may be explained by the low expression of ERa and/or RUNX1 (Figure 4 ). It remains to be investigated whether RUNX3 and/or RUNX1 share with RUNX2 the potential of driving BCa metastasis. Functional differences observed between the three RUNX members in BCa likely reflect various mechanisms regulating their own expression, as well as dissimilarities between their respective C and N termini, which dictate formation of complexes and activation of genes that may be specific for individual RUNX proteins. Among many additional open questions, it remains to be seen how functional redundancy, auto-and cross-regulatory effects, competition, cooperation and/ or heterodimerization 135 of RUNX proteins may contribute to defining their transcriptomes and cellular functions.
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While improving our understanding of the roles of RUNX proteins in BCa, efforts are warranted to translate this knowledge into improvement of BCa patient care. Successful development of RUNX-based therapeutic approaches will unlikely target features shared by all RUNX proteins, such as the RUNT domain or the common co-activator CBFb. 136 Rather, RUNX-based future therapeutics will likely target mechanisms specific for individual RUNX proteins in specific BCa subtypes. For example, the design of RUNX-based anti-metastatic drugs should probably target RUNX2, sparing the tumor suppressor activities of RUNX1 and RUNX3. During the development of such drugs, special attention should be paid to the potential loss of the inhibition of estrogen signaling in ERa-positive tumors. On the other hand, the design of future selective estrogen receptor modulators (SERMs) should take into consideration their effects on RUNX proteins, with the ideal SERM possessing both anti-ER and anti-RUNX2, but not anti-RUNX1 or anti-RUNX3 properties.
